spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Evotec Expands Clinical and Commercial Drug Substance Manufacturing With Acquisition of Central Glass Germany

Evotec



Hamburg, Germany, 25 August 2022
: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.

Going forward, Central Glass Germany GmbH will operate as Evotec Drug Substance (Germany) GmbH (“Evotec DS”). The Company is located on a pharmaceutical manufacturing campus in Halle/Westphalia, Germany and is operating with a team of ~60 chemical manufacturing experts. The facility is EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square meters of floor space.

The acquisition of the Central Glass site in Germany enhances and accelerates Evotec’s strategy of pursuing integrated discovery and development of new medicines that matter. The significant reactor capacity and long-standing chemical expertise brought in by Evotec DS provide a high quality, European-based solution to Evotec’s partners for the development and commercialisation of drug substance. Once integrated into Evotec’s existing drug substance development and manufacturing platform, the new site will offer the Company’s partners highly flexible product lifecycle management strategies, particularly in the field of precision medicines and in rare diseases.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our understanding of diseases continuously grows in depth – and with it the number of rare diseases that we can meaningfully distinguish and target with precision medicine. Evotec DS reinforces our commitment to rare diseases by integrating the manufacturing of such drugs into the drug discovery and development continuum. We very warmly welcome the team into the Evotec family and are excited to leverage their skills and expertise for our partners.”

The contract was signed on 24 August at a purchase price of € 1. The transaction is subject to customary closing conditions and is anticipated to close on 1 November 2022. Evotec intends to invest meaningfully in the coming years to establish the facility as a leading European centre of excellence for rare disease drug substance manufacturing. Earnings accretion is expected to be achieved by 2023/24.
phone +44(0)1235 861 561
email info@evotec.com
web www.evotec.com
email 111 Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies

College Station, Texas, October 24 2022 — FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc. , a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.
More info >>


White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement